Actinogen Medical (ASX:ACW) has launched a new Investor Hub, designed to strengthen engagement with shareholders as the company moves closer to pivotal milestones in its late-stage Alzheimer’s disease trial.
The dedicated platform will centralise ASX announcements, shareholder news, and company updates, while also offering investors a Q&A function to pose questions directly to management. Actinogen said the new hub reflects its commitment to transparency and communication at a critical stage of its development pipeline.
Chief Financial Officer Will Souter said the launch comes at a decisive moment. “Actinogen is pleased to launch the Actinogen Investor Hub as a central platform for shareholders to follow the company’s progress, as we rapidly approach key milestones in our pivotal XanaMIA Phase 2b/3 Alzheimer’s disease trial, with an important interim analysis expected early next year and final results later in 2026.”
Actinogen’s lead compound, Xanamem (emestedastat), is a once-daily oral therapy designed to reduce excess cortisol in the brain by inhibiting the enzyme 11β-HSD1. Elevated cortisol is associated with progression in Alzheimer’s disease and depressive symptoms. The company believes Xanamem has the potential to become a first-in-class treatment for both Alzheimer’s disease and depression.
The XanaMIA Phase 2b/3 trial is enrolling 220 patients with mild to moderate Alzheimer’s, testing whether Xanamem can slow cognitive decline. An open-label extension trial, XanaMIA-DUR, is scheduled to begin in 2026, offering patients continued access to the therapy.
Xanamem has already delivered promising results in depression, with the XanaCIDD Phase 2a trial showing statistically significant improvements in symptoms for patients with treatment-resistant depression. Across eight clinical studies, involving around 400 participants, Xanamem has demonstrated a favourable safety profile and consistent evidence of clinical activity.
As the Alzheimer’s trial progresses, Actinogen is positioning itself at the forefront of efforts to address some of the most challenging neurological and psychiatric conditions. The Investor Hub is designed to ensure shareholders remain informed and connected as the company prepares for its next phase of growth.